Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley C Jordan

Showing results (111-120 of 191) with videos related to

Pageof 20
Sort By:
Transplant Immunology|July 4, 2008
Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitizationGordon D Wu, Yao He, Ning-ning Chai, et al.
Kidney International|November 4, 2022
A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejectionMark Haas, James Mirocha, Edmund Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 28, 2010
Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric reportAshima Gulati, Aditi Sinha, Stanley C Jordan, et al.
Transplantation|August 7, 2019
Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated RejectionBong-Ha Shin, Matthew J Everly, Hao Zhang, et al.
Transplantation|May 13, 2011
Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapyChih-Hung Lai, Kai Cao, Geraldine Ong, et al.
Transplantation|July 29, 2004
Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocolsRobert A Montgomery, Mark A Hardy, Stanley C Jordan, et al.
Pediatric Nephrology (Berlin, Germany)|January 16, 2010
Advances in diagnosing and managing antibody-mediated rejectionStanley C Jordan, Nancy Reinsmoen, Alice Peng, et al.
Transplantation|January 30, 2010
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantationAshley A Vo, Alice Peng, Mieko Toyoda, et al.
Kidney International|January 21, 2017
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodiesMark Haas, James Mirocha, Nancy L Reinsmoen, et al.
The New England Journal of Medicine|July 19, 2008
Rituximab and intravenous immune globulin for desensitization during renal transplantationAshley A Vo, Marina Lukovsky, Mieko Toyoda, et al.
Pageof 20

Showing results (111-120 of 191) with videos related to

Sort By:
Pageof 20
Transplant Immunology|July 4, 2008
Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitizationGordon D Wu, Yao He, Ning-ning Chai, et al.
Kidney International|November 4, 2022
A Banff-based histologic chronicity index is associated with graft loss in patients with a kidney transplant and antibody-mediated rejectionMark Haas, James Mirocha, Edmund Huang, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 28, 2010
Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric reportAshima Gulati, Aditi Sinha, Stanley C Jordan, et al.
Transplantation|August 7, 2019
Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated RejectionBong-Ha Shin, Matthew J Everly, Hao Zhang, et al.
Transplantation|May 13, 2011
Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapyChih-Hung Lai, Kai Cao, Geraldine Ong, et al.
Transplantation|July 29, 2004
Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocolsRobert A Montgomery, Mark A Hardy, Stanley C Jordan, et al.
Pediatric Nephrology (Berlin, Germany)|January 16, 2010
Advances in diagnosing and managing antibody-mediated rejectionStanley C Jordan, Nancy Reinsmoen, Alice Peng, et al.
Transplantation|January 30, 2010
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantationAshley A Vo, Alice Peng, Mieko Toyoda, et al.
Kidney International|January 21, 2017
Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodiesMark Haas, James Mirocha, Nancy L Reinsmoen, et al.
The New England Journal of Medicine|July 19, 2008
Rituximab and intravenous immune globulin for desensitization during renal transplantationAshley A Vo, Marina Lukovsky, Mieko Toyoda, et al.
Pageof 20